<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680300</article-id><article-id pub-id-type="doi">10.3390/vaccines12121365</article-id><article-id pub-id-type="publisher-id">vaccines-12-01365</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>COVID-19 Vaccination and Transient Increase in CD4/CD8 Cell Counts in People with HIV: Evidence from China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanyan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01365" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01365" ref-type="aff">2</xref><xref rid="fn1-vaccines-12-01365" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Yingying</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af3-vaccines-12-01365" ref-type="aff">3</xref><xref rid="fn1-vaccines-12-01365" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-4873-0119</contrib-id><name><surname>Yi</surname><given-names>Yunyun</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af4-vaccines-12-01365" ref-type="aff">4</xref><xref rid="fn1-vaccines-12-01365" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-5499-8756</contrib-id><name><surname>Zhu</surname><given-names>Na</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01365" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01365" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Xinyu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-12-01365" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01365" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-12-01365" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01365" ref-type="aff">2</xref><xref rid="af3-vaccines-12-01365" ref-type="aff">3</xref><xref rid="c1-vaccines-12-01365" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Plans-Rubi&#x000f3;</surname><given-names>Pedro</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01365"><label>1</label>Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China; <email>15736990162@163.com</email> (Y.L.); <email>zhuna202203@163.com</email> (N.Z.); <email>cxy13373145868@163.com</email> (X.C.)</aff><aff id="af2-vaccines-12-01365"><label>2</label>National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China</aff><aff id="af3-vaccines-12-01365"><label>3</label>Center of Integrative Medicine, Peking University Ditan Teaching Hospital, Beijing 100015, China; <email>linyingying0123@163.com</email></aff><aff id="af4-vaccines-12-01365"><label>4</label>Tuberculosis Prevention and Control Key Laboratory, Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, PLA General Hospital, Beijing 100853, China; <email>yyygrace@126.com</email></aff><author-notes><corresp id="c1-vaccines-12-01365"><label>*</label>Correspondence: <email>leaxin@ccmu.edu.cn</email></corresp><fn id="fn1-vaccines-12-01365"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>03</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1365</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Objectives</bold>: Accumulating evidence has confirmed the efficacy and safety of COVID-19 vaccines against SARS-CoV-2 infection. However, the effect of COVID-19 vaccination on immuno-virological parameters in people with HIV (PWH) is uncertain. <bold>Methods</bold>: A total of 372 PWH treated at Beijing Ditan Hospital were included. Unvaccinated PWH were matched 1:3 with vaccinated PWH using a propensity score matching algorithm. Differences in immuno-virological markers between the matched groups were analyzed. The Wilcoxon signed rank test was used to test for changes in CD4 and CD8 counts and HIV viral load over two months around vaccination. In addition, we investigated the long-term changes in HIV-related markers in different vaccination dose groups and in the entire vaccinated population. <bold>Results</bold>: Vaccinated PWH had a higher CD4/CD8 ratio (0.64 (0.49, 0.78) vs. 0.80 (0.56, 1.03), <italic toggle="yes">p</italic> = 0.037) than unvaccinated PWH within a two-month window after the third dose. There were 337 PWH who received COVID-19 vaccination, and 73.9% (n = 249) received three doses of vaccine. We observed a transient increase in CD4 count and CD4/CD8 ratio within a two-month window after vaccination, especially after the second dose (CD4 count: 583.5 (428.5, 706.8) vs. 618.0 (452.0, 744.0), <italic toggle="yes">p</italic> = 0.018; CD4/CD8 ratio: 0.70 (0.50, 0.91) vs. 0.71 (0.53, 0.96), <italic toggle="yes">p</italic> &#x0003c; 0.001)) and the third dose (CD4 count: 575.5 (435.5, 717.0) vs. 577.5 (440.8, 754.8), <italic toggle="yes">p</italic> = 0.001; CD4/CD8 ratio: 0.70 (0.52, 0.93) vs. 0.79 (0.53, 1.00), <italic toggle="yes">p</italic> &#x0003c; 0.001)). Recent CD4 counts and CD4/CD8 ratios were lower than after COVID-19 but remained higher than before COVID-19 in vaccinated PWH. In addition, COVID-19 vaccination had no negative effect on HIV viral load. <bold>Conclusions</bold>: A transient increase in CD4 count and CD4/CD8 ratio was observed after COVID-19 vaccination. However, the enhanced cellular immune response induced by vaccination may diminish over time and return to normal levels. There is no adverse effect of vaccination on HIV viral load.</p></abstract><kwd-group><kwd>HIV</kwd><kwd>COVID-19 vaccine</kwd><kwd>CD4 count</kwd><kwd>CD4/CD8 ratio</kwd><kwd>immune response</kwd></kwd-group><funding-group><award-group><funding-source>Capital&#x02019;s Funds for Health Improvement and Research</funding-source><award-id>2024-1-1203</award-id></award-group><award-group><funding-source>Dengfeng Talent Support Program of Beijing Municipal Administration of Hospitals</funding-source><award-id>DFL20221601</award-id></award-group><award-group><funding-source>High-level Public Health Technical Personnel Construction Project</funding-source><award-id>leaders-03-21</award-id></award-group><funding-statement>This work was supported by the Capital&#x02019;s Funds for Health Improvement and Research (2024-1-1203); Dengfeng Talent Support Program of Beijing Municipal Administration of Hospitals (No.DFL20221601); and High-level Public Health Technical Personnel Construction Project (Subject leaders-03-21).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01365"><title>1. Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel respiratory pathogen causing coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019 [<xref rid="B1-vaccines-12-01365" ref-type="bibr">1</xref>]. Within months, COVID-19 had become a global pandemic, causing significant morbidity, mortality, and socio-economic disruption worldwide [<xref rid="B2-vaccines-12-01365" ref-type="bibr">2</xref>]. People with HIV (PWH) are recognized to be at high risk of SARS-CoV-2 infection [<xref rid="B3-vaccines-12-01365" ref-type="bibr">3</xref>]. Varying degrees of immunodeficiency and chronic inflammation may increase the incidence of serious health complications from COVID-19 compared with people without HIV [<xref rid="B4-vaccines-12-01365" ref-type="bibr">4</xref>].</p><p>Rapid development and administration of COVID-19 vaccine has significantly changed the trajectory of SARS-CoV-2 infection [<xref rid="B5-vaccines-12-01365" ref-type="bibr">5</xref>]. Accumulating evidence has confirmed that COVID-19 vaccination can elicit a satisfactory immune response in PWH comparable to that of the general population, except for cases with low CD4 count recovery [<xref rid="B6-vaccines-12-01365" ref-type="bibr">6</xref>]. Vaccination plays a critical protective role in reducing SARS-CoV-2 transmission, severity of infection, and COVID-19-related mortality in PWH [<xref rid="B7-vaccines-12-01365" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01365" ref-type="bibr">8</xref>]. Although the safety and immunogenicity of SARS-CoV-2 vaccine in PWH have been confirmed, there remain some concerns about its potential effects on HIV immuno-virological markers (CD4 and CD8 counts and HIV viral load) [<xref rid="B9-vaccines-12-01365" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01365" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01365" ref-type="bibr">11</xref>]. Nevertheless, a recent study demonstrated that COVID-19 vaccination can rapidly prime CD4 T spike-specific cells independently of antiviral therapy (ART), leading to a transient increase in CD4 count and a small drop in HIV viral load [<xref rid="B12-vaccines-12-01365" ref-type="bibr">12</xref>]. It is worth noting that the researchers did not include unvaccinated PWH as a control group to compare HIV-related marker changes during the COVID-19 pandemic.</p><p>Reports on the association between COVID-19 vaccine and HIV-related markers are limited. The primary objective of this study was to assess the impact of COVID-19 vaccination on CD4 and CD8 cell counts, HIV viral load, and the durability of cellular immune response. The secondary objective was to investigate whether there were differences in immuno-virological parameters between unvaccinated and vaccinated PWH.</p></sec><sec id="sec2-vaccines-12-01365"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-12-01365"><title>2.1. Patient Population and Study Design</title><p>This retrospective cohort study was conducted in Beijing Ditan Hospital. PWH treated at the outpatient clinic of the Department of Infectious Diseases between January 2024 and June 2024 were enrolled. Prior to the COVID-19 pandemic, all PWH were on ART for &#x02265;6 months and had undetectable HIV viral loads (&#x02264;20 copies/mL) and CD4 counts &#x02265; 100 cells/uL. Exclusion criteria were as follows: (1) change in ART regimen or interruption of ART (n = 20); (2) COVID-19 infection prior to COVID-19 vaccination (n = 15); (3) comorbidity with other immune system diseases (n = 4); (4) malignancy or serious opportunistic infection (n = 11); (5) age &#x0003c; 18 years (n = 1). Ultimately, 372 HIV-positive patients were enrolled in the present study (<xref rid="vaccines-12-01365-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec2dot2-vaccines-12-01365"><title>2.2. Ethical Considerations</title><p>This study was approved by the institutional review board of Beijing Ditan Hospital (approval number: 2021-021-02) and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients provided written informed consent to participate in this study.</p></sec><sec id="sec2dot3-vaccines-12-01365"><title>2.3. Data Collection</title><p>Demographic variables included age, sex, body mass index, personal history, and chronic complications. Laboratory tests included liver biochemical indicators (such as alanine aminotransferase and aspartate aminotransferase), renal function parameters (estimated glomerular filtration rate (eGFR) and creatinine), routine blood tests (such as hemoglobin and platelets), metabolic parameters (such as total cholesterol and glucose), and inflammatory indicators (C-reactive protein). </p><p>In terms of immuno-virological markers, levels of CD4 count, CD8 count, and HIV viral load were collected from PWH at baseline, pre-COVID-19, approximately two months before and after each vaccination, post-COVID-19, and recently. In addition, we investigated information on the timing and dose of the COVID-19 vaccine received by patients.</p><p>According to the policy implemented in China, PWH are entitled to one free laboratory test every six months. In other words, changes in viral-immunological parameters are generally assessed every six months for PWH with stable conditions. Accordingly, the time frame before and after COVID-19 is based on a six-month period. Pre-COVID-19 refers to the period before the outbreak of COVID-19 (i.e., July to December 2019). Post-COVID-19 refers to the period after the end of the COVID-19 pandemic (i.e., January to June 2023). Recent refers to the period from January to June 2024.</p></sec><sec id="sec2dot4-vaccines-12-01365"><title>2.4. Statistical Analysis</title><sec id="sec2dot4dot1-vaccines-12-01365"><title>2.4.1. Propensity Score Matching Analysis</title><p>As previously reported, propensity score matching is a valuable tool to reduce inherent selection bias and control for potential confounders in observational studies [<xref rid="B13-vaccines-12-01365" ref-type="bibr">13</xref>]. Therefore, the propensity score was calculated with an a priori logistic regression model based on 11 covariates, including age, sex, body mass index, smoking, drinking, chronic complications, and CD4 and CD8 counts before COVID-19. These covariates are listed in <xref rid="vaccines-12-01365-t001" ref-type="table">Table 1</xref>. Unvaccinated PWH were matched 1:3 with vaccinated patients. After propensity score matching, 130 observations (34 in the unvaccinated group and 96 in the vaccinated group) were retained for further analysis.</p></sec><sec id="sec2dot4dot2-vaccines-12-01365"><title>2.4.2. Comparison of Variables</title><p>Continuous variables were expressed as mean &#x000b1; standard deviation or median (interquartile range) in case of skewed distribution. Differences between groups were analyzed by Student&#x02019;s <italic toggle="yes">t</italic> test or Mann&#x02013;Whitney U test. Categorical variables were presented as percentages (%) and their statistical analysis was performed by the Chi-square test or Fisher&#x02019;s exact test. A non-parametric test (Wilcoxon signed rank test) was used to compare the change in HIV viro-immunological markers before and after vaccination. Data analysis was performed with SPSS version 26.0. Figures were generated using R version 4.1.2. Statistical significance was set at <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></sec></sec><sec id="sec2dot5-vaccines-12-01365"><title>2.5. Vaccines</title><p>The COVID-19 vaccines received by PWH were the inactivated vaccines (Vero cells) CoronaVac (Sinovac, Beijing, China) and Covilo (Sinopharm, Beijing, China). CoronaVac contains 3 &#x000b5;g in 0.5 mL of beta-propiolactone-inactivated SARS-CoV-2 from the CN02 strain grown in Vero cells and aluminum hydroxide as an adjuvant. Covilo contains 4 &#x000b5;g in 0.5 mL of beta-propiolactone-inactivated SARS-CoV-2 from the SARS-CoV-2019nCoV-CDC-Tan-HB02 strain grown in Vero cells and aluminum hydroxide as an adjuvant. Both inactivated vaccines were administered in doses of 0.5 ml [<xref rid="B14-vaccines-12-01365" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01365" ref-type="bibr">15</xref>]. Specifically, 180 PWH received CoronaVac vaccine and 157 received Covilo vaccine. </p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01365"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01365"><title>3.1. Baseline Characteristics</title><p>Baseline characteristics of PWH before and after propensity score matching are shown in <xref rid="vaccines-12-01365-t001" ref-type="table">Table 1</xref>. A total of 34 unvaccinated PWH were matched with 96 vaccinated PWH. In the two matched groups, the mean age was approximately 33 years, and most were male. The proportion of patients with chronic complications was low. In addition, the pre-COVID-19 CD4 count and CD4/CD8 ratio were similar between the two groups (<italic toggle="yes">p</italic> &#x0003e; 0.05). </p><p><xref rid="app1-vaccines-12-01365" ref-type="app">Supplementary Table S1</xref> shows the laboratory characteristics in the unvaccinated and vaccinated PWH groups. There were no differences in liver function, kidney function, metabolic parameters, routine blood counts, and inflammatory indicators between the two groups (<italic toggle="yes">p</italic> &#x0003e; 0.05).</p><table-wrap position="anchor" id="vaccines-12-01365-t001"><object-id pub-id-type="pii">vaccines-12-01365-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Characteristics</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Unadjusted</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">After Propensity Score Matching</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unvaccinated<break/>(n = 35)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated<break/>(n = 337)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unvaccinated<break/>(n = 34)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated<break/>(n = 96)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" rowspan="1">Personal History</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.4 &#x000b1; 10.0</td><td align="center" valign="middle" rowspan="1" colspan="1">31.3 &#x000b1; 8.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.160</td><td align="center" valign="middle" rowspan="1" colspan="1">33.5 &#x000b1; 10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">33.8 &#x000b1; 8.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.866</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (97.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">325 (96.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.767</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (97.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (96.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">23.6 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">23.7 &#x000b1; 2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.750</td><td align="center" valign="middle" rowspan="1" colspan="1">23.6 &#x000b1; 2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">23.5 &#x000b1; 2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.763</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Smoking, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (28.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">142 (42.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.120</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (29.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (40.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.246</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drinking, n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (17.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119 (35.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.030</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (17.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (22.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.521</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Comorbidities, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (4.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.710</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.456</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (14.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (7.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.183</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (11.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.759</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cardiovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (1.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.450</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.456</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (14.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (9.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.371</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (14.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (13.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Pre-COVID-19 HIV markers </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count</td><td align="center" valign="middle" rowspan="1" colspan="1">468.0 (356.0, 636.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">562.0 (402.0, 740.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">472.0 (389.0, 644.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">490.0 (345.0, 659.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.962</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56 (0.44, 0.81)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65 (0.47, 0.89)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.236</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.59 (0.44, 0.81)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 (0.38, 0.79)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.571</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean &#x000b1; standard deviation, number (percentage), or median (interquartile range). Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3dot2-vaccines-12-01365"><title>3.2. ART and HIV Markers in the Matched Cohort</title><p><xref rid="vaccines-12-01365-t002" ref-type="table">Table 2</xref> shows that the ART regimen was similar between the matched groups (<italic toggle="yes">p</italic> &#x0003e; 0.05). Unvaccinated PWH had similar primary infection rates (73.5% vs. 79.2%) and repeat infection rates (5.9% vs. 9.4%) compared to vaccinated individuals. Two months after the first vaccination, there was no significant difference in CD4 count and CD4/CD8 ratio between the two groups (<italic toggle="yes">p</italic> &#x0003e; 0.05). However, vaccinated PWH had a higher CD4/CD8 ratio (0.64 (0.49, 0.78) vs. 0.80 (0.56, 1.03), <italic toggle="yes">p</italic> = 0.037) than unvaccinated PWH within a two-month window after the third dose. Notably, only 13 unvaccinated PWH had laboratory tests in the two months after the vaccinated group received the second dose, so we did not analyze this time point. Although there was no statistical difference, post-COVID-19 and recent CD4 counts and CD4/CD8 ratios were slightly higher in vaccinated PWH. In addition, we found that there was no significant difference in the ratio of immunological parameters between post-COVID-19 and pre-COVID-19 (<italic toggle="yes">p</italic> &#x0003e; 0.05).</p></sec><sec id="sec3dot3-vaccines-12-01365"><title>3.3. Changes in CD4 and CD8 Counts Before and After Vaccination</title><p>Due to the impact of COVID-19 epidemic control, patients were unable to attend outpatient clinics for regular HIV immuno-virological marker testing. Only 48 PWH accepted testing within two months of the first vaccination. Although there was no significant change in CD4 count (592.5 (421.0, 709.0) vs. 586.0 (461.5, 718.0), <italic toggle="yes">p</italic> = 0.072), the CD4/CD8 ratio (0.74 (0.60, 0.98) vs. 0.82 (0.68, 0.96), <italic toggle="yes">p</italic> = 0.010) was significantly increased after vaccination (<xref rid="vaccines-12-01365-f002" ref-type="fig">Figure 2</xref>A,B). Of those who received a second dose, 124 individuals underwent laboratory testing. There were significant differences in CD4 count (583.5 (428.5, 706.8) vs. 618.0 (452.0, 744.0), <italic toggle="yes">p</italic> = 0.018) and CD4/CD8 ratio (0.70 (0.50, 0.91) vs. 0.71 (0.53, 0.96), <italic toggle="yes">p</italic> &#x0003c; 0.001) (<xref rid="vaccines-12-01365-f002" ref-type="fig">Figure 2</xref>C,D). After the third vaccination, 122 individuals underwent immuno-virological marker testing. CD4 cell count (575.5 (435.5, 717.0) vs. 577.5 (440.8, 754.8), <italic toggle="yes">p</italic> = 0.001) and CD4/CD8 ratio (0.70 (0.52, 0.93) vs. 0.79 (0.53, 1.00), <italic toggle="yes">p</italic> &#x0003c; 0.001) were higher than before vaccination (<xref rid="vaccines-12-01365-f002" ref-type="fig">Figure 2</xref>E,F). </p><p>We compared the difference in immunological parameters between two months after each vaccination and the post-COVID-19 period. However, there was no significant difference in CD4 count and CD4/CD8 ratio between post-vaccination and post-COVID-19 (<italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="app1-vaccines-12-01365" ref-type="app">Supplementary Table S2</xref>). Regarding the overall change in HIV markers in 337 vaccinated PWH, we found that the most recent CD4 count (644.0 (478.5, 813.0) vs. 669.0 (456.0, 861.5), <italic toggle="yes">p</italic> = 0.001) and CD4/CD8 ratio (0.77 (0.59, 1.08) vs. 0.79 (0.59, 0. 99), <italic toggle="yes">p</italic> = 0.005) were lower than after COVID-19 but remained higher than the pre-COVID-19 CD4 count (644.0 (478.5, 813.0) vs. 562.0 (401.5, 741.0), <italic toggle="yes">p</italic> &#x0003c; 0.001) and CD4/CD8 ratio (0.77 (0.59, 1.08) vs. 0.65 (0.47, 0.90), <italic toggle="yes">p</italic> &#x0003c; 0.001) (<xref rid="vaccines-12-01365-f003" ref-type="fig">Figure 3</xref>A,B). Notably, there was no significant difference in immuno-virological parameters between the two inactivated vaccines.</p><p>Similar results were observed in the subgroup analysis, as described in <xref rid="vaccines-12-01365-t003" ref-type="table">Table 3</xref>. Higher levels of CD4 count and CD4/CD8 ratio were observed after vaccination in the group with CD4 count &#x0003e; 500 cells/uL, CD4/CD8 ratio &#x0003e; 1, ART initiation &#x0003e; 1 year, and no SARS-CoV-2 infection.</p></sec><sec id="sec3dot4-vaccines-12-01365"><title>3.4. Association Between Changes in CD4 Count and CD4/CD8 Ratio and Vaccine Doses</title><p>A total of 337 PWH received COVID-19 vaccine, of which 11 received one dose of vaccine, 77 received two doses, and 249 received three doses. There were no differences in personal history and comorbidities between PWH with different vaccination doses. CD4 count, CD8 count, and CD4/CD8 ratio were similar between the dose groups at baseline and before COVID-19 (<italic toggle="yes">p</italic> &#x0003e; 0.05). The median time of ART initiation was four years among vaccinated PWH (<xref rid="app1-vaccines-12-01365" ref-type="app">Supplementary Table S3</xref>).</p><p>As shown in <xref rid="app1-vaccines-12-01365" ref-type="app">Supplementary Table S4</xref> and <xref rid="vaccines-12-01365-f004" ref-type="fig">Figure 4</xref>, the three groups had similar CD4 counts and CD4/CD8 ratios before COVID-19 (all <italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="vaccines-12-01365-f004" ref-type="fig">Figure 4</xref>A,B). PWH who received three doses of vaccine had higher post-pandemic CD4 counts than those who received two doses (685.0 (494.0, 877.0) vs. 583.0 (414.0, 833.0), <italic toggle="yes">p</italic> = 0.031) (<xref rid="vaccines-12-01365-f004" ref-type="fig">Figure 4</xref>C). However, there was no significant difference in the CD4/CD8 ratio between the three groups (<italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="vaccines-12-01365-f004" ref-type="fig">Figure 4</xref>D). According to recent laboratory tests, the three groups had similar CD4 counts and CD4/CD8 ratios (all <italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="vaccines-12-01365-f004" ref-type="fig">Figure 4</xref>E,F).</p></sec><sec id="sec3dot5-vaccines-12-01365"><title>3.5. HIV Viral Load During the Epidemic</title><p>In this study, we found no adverse effect of COVID-19 vaccination or SARS-CoV-2 infection on HIV viral load. As we only included PWH with viral control &#x02264;20 copies/mL, data on undetectable HIV viral load are not shown in figures or tables throughout this study.</p></sec><sec id="sec3dot6-vaccines-12-01365"><title>3.6. Changes in Biochemical Indicators in PWH with Previous COVID-19 Infection</title><p>We evaluated the long-term effects of COVID-19 infection on liver and kidney function, metabolism, and inflammation in PWH. There were no significant differences in serum levels of alanine aminotransferase, aspartate aminotransferase, glucose, total cholesterol, triglyceride, and C-reactive protein before and after COVID-19. Albumin and eGFR levels were lower after COVID-19 than before COVID-19, but the magnitude of the change may be of negligible clinical significance (<xref rid="app1-vaccines-12-01365" ref-type="app">Supplementary Table S5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01365"><title>4. Discussion</title><p>In this study, we found that the following: (1) approximately 90.6% (337 cases) of PWH received COVID-19 vaccination, of whom 11 received one dose, 77 received two doses, and 249 received three doses; (2) there was a transient increase in CD4 counts and CD4/CD8 ratios within two months of vaccination, especially after the second and third doses; (3) PWH who received three vaccine doses had higher post-pandemic CD4 counts than those who received two doses and one dose; (4) although recent CD4 counts and CD4/CD8 ratios were lower than after COVID-19, they were still higher than before the pandemic; (5) vaccinated PWH had a higher CD4/CD8 ratio than unvaccinated PWH within a two-month window after the third dose, but the two groups had similar CD4 counts and CD4/CD8 ratios in the post-pandemic and recent periods. </p><p>Vaccination is recognized as one of the most effective public health interventions against the COVID-19 pandemic [<xref rid="B16-vaccines-12-01365" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01365" ref-type="bibr">17</xref>]. COVID-19 vaccine is recommended for PWH, especially those with CD4 count &#x0003c;200 cells/uL, unsuppressed/detectable HIV viral load, or opportunistic infection, who are considered a high-priority group for vaccination [<xref rid="B18-vaccines-12-01365" ref-type="bibr">18</xref>]. It is well established that COVID-19 vaccine played a key role in protecting PWH against SARS-CoV-2 infection, reducing virus transmission, infection severity, and COVID-19-associated mortality [<xref rid="B19-vaccines-12-01365" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01365" ref-type="bibr">20</xref>]. However, limited evidence suggests that vaccines may have adverse effects on HIV immuno-virological markers. Previous reports have shown that streptococcus pneumonia, hepatitis B virus, and influenza vaccinations can cause transient increases in HIV viral load [<xref rid="B21-vaccines-12-01365" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-01365" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01365" ref-type="bibr">23</xref>]. In addition, COVID-19 vaccine may induce suboptimal immune responses in PWH due to persistent immune dysfunction and exhaustion, even after HIV suppression and CD4 cell restoration with ART [<xref rid="B24-vaccines-12-01365" ref-type="bibr">24</xref>]. Therefore, it is necessary to evaluate the potential impact of COVID-19 vaccination on HIV immunity and virology.</p><p>To the best of our knowledge, this study is the first to analyze the association between immuno-virological markers and SARS-CoV-2 vaccination in Chinese PWH during the three-year COVID-19 pandemic. We found that 337 (90.6%) PWH received COVID-19 vaccination, of which 11 received one dose, 77 received two doses, and 249 received three doses. A meta-analysis of COVID-19 vaccine uptake showed that approximately 50% of PWH worldwide received at least one dose of the vaccine; stratified by WHO region, uptake was highest in the European region at 90.1%, followed by the Southeast Asian region at 78.9% and the Americas at 71.6% [<xref rid="B25-vaccines-12-01365" ref-type="bibr">25</xref>]. COVID-19 vaccine hesitancy and uptake among PWH remains highly variable in different WHO regions and socio-demographic contexts around the world. Evidence suggests that the rate of COVID-19 vaccine hesitancy in PWH is significantly higher than in HIV-uninfected individuals [<xref rid="B26-vaccines-12-01365" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01365" ref-type="bibr">27</xref>]. One of the most important concerns may be the potential effects of the vaccine on HIV immuno-virological parameters.</p><p>We observed a transient increase in CD4 count and CD4/CD8 ratio over a two-month window following COVID-19 vaccination, particularly after the second and third doses. Our previous studies have shown that COVID-19 booster shots are effective in PWH, resulting in increases in CD4 cell counts and neutralizing antibodies that last for up to six months [<xref rid="B28-vaccines-12-01365" ref-type="bibr">28</xref>]. Consistent with our findings, a recent study from Italy also showed a transient increase in CD4 count after COVID-19 vaccination, and the results remained after restricting the analysis to virosuppressed PWH with CD4 &#x02264;200 cells/uL and more than six months of ART prior to vaccination [<xref rid="B12-vaccines-12-01365" ref-type="bibr">12</xref>]. In addition, vaccine-induced spike-specific T-cell responses are equivalent after two or three doses of COVID-19 vaccination in PWH and HIV-negative controls [<xref rid="B29-vaccines-12-01365" ref-type="bibr">29</xref>]. This suggests that the transient increase in CD4 cell frequencies may be associated with rapid priming of CD4 T spike-specific cells by COVID-19 vaccine, independent of ART [<xref rid="B30-vaccines-12-01365" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01365" ref-type="bibr">31</xref>]. The observed association between CD4 cell count and COVID-19 vaccine is not an epiphenomenon; rather, vaccination may have a direct potentiating effect on cellular immune responses in PWH.</p><p>In the subgroup analysis, we found that CD4 cell counts and CD4/CD8 ratios were also increased after vaccination in PWH on ART &#x0003e;1 year or with CD4 cell counts &#x0003e;500 cells/uL. In terms of overall HIV marker fluctuation, recent CD4 counts and CD4/CD8 ratios were lower than in the post-pandemic period but remained higher than before COVID-19 in the vaccinated PWH group. In addition, we compared changes in HIV immunological parameters between vaccinated and unvaccinated PWH using propensity score matching analysis. Vaccinated PWH had a higher CD4/CD8 ratio than unvaccinated PWH within a two-month window after the third dose. Although vaccinated PWH had slightly elevated CD4 counts and CD4/CD8 ratios compared with unvaccinated controls in the post-pandemic and recent periods, the magnitude of the changes was not statistically different. This phenomenon may be related to the following reasons. First, we included a small sample size of 34 unvaccinated PWH, which may limit the statistical power of this study. Second, the difference in immunological parameters between the two groups diminished as the level of vaccination-induced cellular response decreased over time. A collection of evidence from available studies also suggests that T-cell responses are well maintained six months after COVID-19 vaccination, whereas humoral responses appear to be significantly attenuated six months after initial vaccination [<xref rid="B32-vaccines-12-01365" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-12-01365" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01365" ref-type="bibr">34</xref>]. It is now well established that the humoral and cellular responses elicited by either natural SAR-CoV-2 infection or vaccination in PWH wane significantly over time [<xref rid="B35-vaccines-12-01365" ref-type="bibr">35</xref>]. However, the durability and waning rate of immune response varies between different vaccine regimens, and booster doses may compensate for waning efficacy [<xref rid="B36-vaccines-12-01365" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-01365" ref-type="bibr">37</xref>]. </p><p>An additional dose of SARS-CoV-2 vaccine not only boosts immunity but also prolongs protection [<xref rid="B38-vaccines-12-01365" ref-type="bibr">38</xref>]. Global guidelines also recommend extending the COVID-19 vaccine series in PWH and providing booster doses in moderate to severe immunosuppression [<xref rid="B18-vaccines-12-01365" ref-type="bibr">18</xref>,<xref rid="B39-vaccines-12-01365" ref-type="bibr">39</xref>]. We observed an increasing trend in CD4 count and CD4/CD8 ratio with extended vaccine doses, with PWH in the three-dose vaccine group having higher post-COVID-19 CD4 counts than those in the two-dose and one-dose groups. Previous studies have shown that a third dose of SARS-CoV-2 mRNA vaccine significantly enhances the immune response in PWH, including those with advanced HIV infection [<xref rid="B40-vaccines-12-01365" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-01365" ref-type="bibr">41</xref>]. Repeated exposure to SARS-CoV-2 antigen appears to have a maturational effect, inducing both enhanced T-cell effector function and diverse response potential to spike proteins and other SARS-CoV-2 internal proteins [<xref rid="B42-vaccines-12-01365" ref-type="bibr">42</xref>]. In addition, clinical evidence suggests that a third dose of vaccine effectively reduces the risk of breakthrough infection in PWH [<xref rid="B43-vaccines-12-01365" ref-type="bibr">43</xref>]. Thus, repeated exposure to SARS-CoV-2 (either by infection or vaccination) may enhance immune responses in PWH [<xref rid="B44-vaccines-12-01365" ref-type="bibr">44</xref>]. </p><p>Not only the immune response but also the HIV viral load may be affected by COVID-19 vaccination. Reports by Vergori et al. [<xref rid="B12-vaccines-12-01365" ref-type="bibr">12</xref>] suggest a small decrease in HIV viral load within one month of COVID-19 vaccination in PWH. However, Matveev et al. [<xref rid="B45-vaccines-12-01365" ref-type="bibr">45</xref>] found a slight increase in the frequency of detectable viremia after the two doses of COVID-19 vaccine in older PWH. Even without HIV infection, advanced age is associated with an increased risk of immune dysfunction and immunosenescence [<xref rid="B46-vaccines-12-01365" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-12-01365" ref-type="bibr">47</xref>]. Thus, HIV viral load may take the opportunity to increase when the compromised immune system struggles to mobilize in response to the SARS-CoV-2 vaccine in the elderly HIV population. In contrast to the findings of the two previous studies, our study found no apparent change in virological parameters in PWH during the COVID-19 pandemic. Because only PWH with an undetectable HIV viral load (&#x02264;20 copies/ml) were included in this study, we were unable to assess whether vaccine responses could lead to further reductions in HIV viral load. It is certain that neither vaccination nor SARS-CoV-2 infection caused virological failure in the present study.</p><p>The SARS-CoV-2 virus attacks not only the lungs but also other organs such as the liver and kidneys, leading to serious complications [<xref rid="B48-vaccines-12-01365" ref-type="bibr">48</xref>]. Previous reports have focused on organ damage during the acute phase of SARS-CoV-2 infection, but whether this damage is long-lasting in immunosuppressed populations is unclear [<xref rid="B49-vaccines-12-01365" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-01365" ref-type="bibr">50</xref>]. Our study investigated the most recent levels of liver and kidney function parameters, metabolic markers, and inflammatory markers in PWH with previous COVID-19 infection. Although a statistically significant decrease in eGFR and albumin levels was observed, the magnitude of the changes was of negligible clinical significance. There were no significant effects of SARS-CoV-2 virus on other biomarkers. However, our study only included PWH with CD4 &#x0003e;100 cells/uL and viral suppression, so the results are not representative of the whole HIV population. In addition, the small sample size may lead to some random effects and false-negative results. Given the potential for chronic and systemic damage left by SARS-CoV-2 infection, future studies with long-term follow-up need to investigate the possible effects of long COVID in PWH [<xref rid="B51-vaccines-12-01365" ref-type="bibr">51</xref>]. </p><p>Vaccination protects against the severe SARS-CoV-2 infection in PWH, but its effect on the state of general immunity, including CD4 cells, CD4/CD8 ratio, and HIV viral load, is not fully understood. Although COVID-19 has become part of a long list of common infectious respiratory diseases, some PWH remain at risk of re-infection and severe infection [<xref rid="B52-vaccines-12-01365" ref-type="bibr">52</xref>]. In fact, a significant proportion of PWH have COVID-19 vaccine hesitancy and remain unvaccinated [<xref rid="B53-vaccines-12-01365" ref-type="bibr">53</xref>]. Therefore, it is necessary to investigate the long-term effects of COVID-19 vaccine on PWH. In this study, we first evaluated the changes in immuno-virological parameters at a median of three years after COVID-19 vaccination in Chinese PWH. We found that the SARS-CoV-2 vaccine induced a good immune response in PWH: a transient increase in CD4 count and CD4/CD8 ratio over a two-month window after COVID-19 vaccination. In addition, there were no adverse effects on immuno-virological parameters over a median follow-up of three years. Our results may provide evidence for the long-term safety of COVID-19 vaccine, especially with regard to immuno-virological parameters.</p><p>Some limitations should be noted. First, we included a small sample size of PWH, which makes our results less conclusive and comprehensive. Second, HIV-related markers were assessed approximately two months after vaccination; such a long interval may mask the true change in these markers. Third, due to the impact of epidemic containment, only a subset of patients received regular viro-immunological marker testing after each vaccine dose, further limiting the accuracy and reliability of the results. In addition, some of the PWH with advanced immunosuppression (pre-COVID-19 CD4 count 100&#x02013;350 cells/uL) were included, so the increases in CD4 counts may be partly related to ART. Finally, we did not evaluate the association between vaccination and clinical efficacy endpoints, such as SARS-CoV-2 infection rates and severity of infection.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01365"><title>5. Conclusions</title><p>This study presented real-world data showing that there was no adverse effect of COVID-19 vaccine on immuno-virological markers in PWH. In contrast, we found a transient increase in CD4 count and CD4/CD8 ratio after COVID-19 vaccination. However, the cellular immune response induced by vaccination may attenuate over time and return to normal levels. Our results provide long-term evidence of the safety of COVID-19 vaccination, particularly in terms of immuno-virological parameters, which is a positive message for future campaigns. Future studies are needed to investigate the impact of COVID-19 vaccination on the immune response in PWH, including vaccine modalities, doses required, and time interval.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to express our gratitude to all the patients who participated in this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01365"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12121365/s1">https://www.mdpi.com/article/10.3390/vaccines12121365/s1</uri>, Table S1: Pre-COVID-19 biochemical indicators between the matched groups; Table S2: Comparison of CD4/CD8 counts between post-vaccination and post-COVID-19; Table S3: Baseline information on PWH receiving different vaccination doses; Table S4: HIV markers in PWH receiving different vaccination doses; Table S5: Changes in biochemical indicators in PWH with previous COVID-19 infection.</p><supplementary-material id="vaccines-12-01365-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01365-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, Y.L. (Yanyan Li) and X.L.; methodology, Y.L. (Yanyan Li), Y.L. (Yingying Lin), and Y.Y.; software, Y.L. (Yanyan Li); validation, N.Z. and X.C. formal analysis, Y.L. (Yanyan Li); investigation, Y.L. (Yingying Lin) and Y.Y.; data curation, Y.L. (Yingying Lin) and Y.Y.; writing&#x02014;original draft preparation, Y.L. (Yanyan Li); writing&#x02014;review and editing, X.L.; visualization, Y.L. (Yanyan Li); supervision, X.L.; project administration, X.L.; funding acquisition, X.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was approved by the institutional review board of Beijing Ditan Hospital (approval number: 2021-021-02) and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent has been obtained from the patients to publish this paper.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets generated and analyzed during the present study are not publicly available due to the restrictions imposed by the Beijing Ditan Hospital who is the data owner. The authors used this dataset under an agreement with the Beijing Ditan Hospital for the current study. If anyone wants to access the data used in the study for reasonable requests, please contact the corresponding author, Xin Li.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01365"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Markov</surname><given-names>P.V.</given-names></name>
<name><surname>Ghafari</surname><given-names>M.</given-names></name>
<name><surname>Beer</surname><given-names>M.</given-names></name>
<name><surname>Lythgoe</surname><given-names>K.</given-names></name>
<name><surname>Simmonds</surname><given-names>P.</given-names></name>
<name><surname>Stilianakis</surname><given-names>N.I.</given-names></name>
<name><surname>Katzourakis</surname><given-names>A.</given-names></name>
</person-group><article-title>The evolution of SARS-CoV-2</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>361</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1038/s41579-023-00878-2</pub-id><pub-id pub-id-type="pmid">37020110</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01365"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bash</surname><given-names>K.</given-names></name>
<name><surname>Sacha</surname><given-names>G.</given-names></name>
<name><surname>Latifi</surname><given-names>M.</given-names></name>
</person-group><article-title>COVID-19: A management update</article-title><source>Cleve. Clin. J. Med.</source><year>2023</year><volume>90</volume><fpage>677</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.3949/ccjm.90a.22102</pub-id><pub-id pub-id-type="pmid">37914200</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01365"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brolly</surname><given-names>J.</given-names></name>
<name><surname>Chadwick</surname><given-names>D.R.</given-names></name>
</person-group><article-title>COVID-19 infection in people living with HIV</article-title><source>Br. Med. Bull.</source><year>2023</year><volume>147</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/bmb/ldac031</pub-id><pub-id pub-id-type="pmid">37312594</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01365"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thornhill</surname><given-names>J.</given-names></name>
<name><surname>Orkin</surname><given-names>C.</given-names></name>
<name><surname>Cevik</surname><given-names>M.</given-names></name>
</person-group><article-title>Estimating the global impact of coronavirus disease 2019 on people living with HIV</article-title><source>Curr. Opin. Infect. Dis.</source><year>2023</year><volume>36</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000898</pub-id><pub-id pub-id-type="pmid">36729763</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01365"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ao</surname><given-names>D.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
</person-group><article-title>Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>466</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01724-w</pub-id><pub-id pub-id-type="pmid">38129394</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01365"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levy</surname><given-names>I.</given-names></name>
<name><surname>Rahav</surname><given-names>G.</given-names></name>
</person-group><article-title>The effect of HIV on COVID-19 vaccine responses</article-title><source>Curr. Opin. HIV AIDS</source><year>2023</year><volume>18</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000790</pub-id><pub-id pub-id-type="pmid">36943427</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01365"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salo</surname><given-names>J.</given-names></name>
<name><surname>H&#x000e4;gg</surname><given-names>M.</given-names></name>
<name><surname>Kortelainen</surname><given-names>M.</given-names></name>
<name><surname>Leino</surname><given-names>T.</given-names></name>
<name><surname>Saxell</surname><given-names>T.</given-names></name>
<name><surname>Siikanen</surname><given-names>M.</given-names></name>
<name><surname>S&#x000e4;&#x000e4;ksvuori</surname><given-names>L.</given-names></name>
</person-group><article-title>The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers&#x02019; unvaccinated household members</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>1162</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-28825-4</pub-id><pub-id pub-id-type="pmid">35246536</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01365"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>J.D.</given-names></name>
<name><surname>Leonard</surname><given-names>S.</given-names></name>
<name><surname>Hoggatt</surname><given-names>K.J.</given-names></name>
<name><surname>Boscardin</surname><given-names>W.J.</given-names></name>
<name><surname>Lum</surname><given-names>E.N.</given-names></name>
<name><surname>Moss-Vazquez</surname><given-names>T.A.</given-names></name>
<name><surname>Andino</surname><given-names>R.</given-names></name>
<name><surname>Wong</surname><given-names>J.K.</given-names></name>
<name><surname>Byers</surname><given-names>A.</given-names></name>
<name><surname>Bravata</surname><given-names>D.M.</given-names></name>
<etal/>
</person-group><article-title>Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>1427</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.17985</pub-id><pub-id pub-id-type="pmid">36156706</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01365"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bozzi</surname><given-names>G.</given-names></name>
<name><surname>Lombardi</surname><given-names>A.</given-names></name>
<name><surname>Ludovisi</surname><given-names>S.</given-names></name>
<name><surname>Muscatello</surname><given-names>A.</given-names></name>
<name><surname>Manganaro</surname><given-names>L.</given-names></name>
<name><surname>Cattaneo</surname><given-names>D.</given-names></name>
<name><surname>Gori</surname><given-names>A.</given-names></name>
<name><surname>Bandera</surname><given-names>A.</given-names></name>
</person-group><article-title>Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>113</volume><fpage>125</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.10.021</pub-id><pub-id pub-id-type="pmid">34666164</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01365"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levy</surname><given-names>I.</given-names></name>
<name><surname>Wieder-Finesod</surname><given-names>A.</given-names></name>
<name><surname>Litchevsky</surname><given-names>V.</given-names></name>
<name><surname>Biber</surname><given-names>A.</given-names></name>
<name><surname>Indenbaum</surname><given-names>V.</given-names></name>
<name><surname>Olmer</surname><given-names>L.</given-names></name>
<name><surname>Huppert</surname><given-names>A.</given-names></name>
<name><surname>Mor</surname><given-names>O.</given-names></name>
<name><surname>Goldstein</surname><given-names>M.</given-names></name>
<name><surname>Levin</surname><given-names>E.G.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><fpage>1851</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.07.031</pub-id><pub-id pub-id-type="pmid">34438069</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01365"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fusco</surname><given-names>F.M.</given-names></name>
<name><surname>Carleo</surname><given-names>M.A.</given-names></name>
<name><surname>Sangiovanni</surname><given-names>N.</given-names></name>
<name><surname>D&#x02019;Abbraccio</surname><given-names>M.</given-names></name>
<name><surname>Tambaro</surname><given-names>O.</given-names></name>
<name><surname>Borrelli</surname><given-names>F.</given-names></name>
<name><surname>Viglietti</surname><given-names>R.</given-names></name>
<name><surname>Camaioni</surname><given-names>C.</given-names></name>
<name><surname>Bruner</surname><given-names>V.</given-names></name>
<name><surname>Falanga</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Does COVID-19 Vaccination with BNT162b2 Influence HIV-Related Immunological and Virological Markers? Data from 235 Persons Living with HIV at Cotugno Hospital, Naples, Italy: Immune Response After Second and Third Doses, and Influence on Immunovirological Markers</article-title><source>Viral Immunol.</source><year>2023</year><volume>36</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1089/vim.2022.0182</pub-id><pub-id pub-id-type="pmid">37140991</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01365"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vergori</surname><given-names>A.</given-names></name>
<name><surname>Cozzi-Lepri</surname><given-names>A.</given-names></name>
<name><surname>Tavelli</surname><given-names>A.</given-names></name>
<name><surname>Mazzotta</surname><given-names>V.</given-names></name>
<name><surname>Azzini</surname><given-names>A.M.</given-names></name>
<name><surname>Gagliardini</surname><given-names>R.</given-names></name>
<name><surname>Mastrorosa</surname><given-names>I.</given-names></name>
<name><surname>Latini</surname><given-names>A.</given-names></name>
<name><surname>Pellican&#x000f2;</surname><given-names>G.</given-names></name>
<name><surname>Taramasso</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV</article-title><source>Int. J. Infect. Dis.</source><year>2024</year><volume>144</volume><fpage>107065</fpage><pub-id pub-id-type="doi">10.1016/j.ijid.2024.107065</pub-id><pub-id pub-id-type="pmid">38643867</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01365"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.W.</given-names></name>
<name><surname>Maldonado</surname><given-names>D.R.</given-names></name>
<name><surname>Kowalski</surname><given-names>B.L.</given-names></name>
<name><surname>Miecznikowski</surname><given-names>K.B.</given-names></name>
<name><surname>Kyin</surname><given-names>C.</given-names></name>
<name><surname>Gornbein</surname><given-names>J.A.</given-names></name>
<name><surname>Domb</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Best Practice Guidelines for Propensity Score Methods in Medical Research: Consideration on Theory, Implementation, and Reporting. A Review</article-title><source>Arthroscopy</source><year>2022</year><volume>38</volume><fpage>632</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/j.arthro.2021.06.037</pub-id><pub-id pub-id-type="pmid">34547404</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01365"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Kaabi</surname><given-names>N.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Xia</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Al Qahtani</surname><given-names>M.M.</given-names></name>
<name><surname>Abdulrazzaq</surname><given-names>N.</given-names></name>
<name><surname>Al Nusair</surname><given-names>M.</given-names></name>
<name><surname>Hassany</surname><given-names>M.</given-names></name>
<name><surname>Jawad</surname><given-names>J.S.</given-names></name>
<name><surname>Abdalla</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.8565</pub-id><pub-id pub-id-type="pmid">34037666</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01365"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Yao</surname><given-names>P.</given-names></name>
<name><surname>Xu</surname><given-names>N.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Liao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Mao</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: A 6-month population-based cohort study</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>939311</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.939311</pub-id><pub-id pub-id-type="pmid">36032136</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01365"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>G.</given-names></name>
<name><surname>Pan</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Chu</surname><given-names>K.</given-names></name>
<name><surname>Han</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Tang</surname><given-names>R.</given-names></name>
<name><surname>Yin</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x02013;59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmid">33217362</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01365"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>C.</given-names></name>
<name><surname>Shao</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><year>2022</year><volume>114</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.11.009</pub-id><pub-id pub-id-type="pmid">34800687</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01365"><label>18.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><article-title>COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-28">(accessed on 28 March 2023)</date-in-citation></element-citation></ref><ref id="B19-vaccines-12-01365"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beladiya</surname><given-names>J.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Vasava</surname><given-names>Y.</given-names></name>
<name><surname>Parmar</surname><given-names>K.</given-names></name>
<name><surname>Patel</surname><given-names>D.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Dholakia</surname><given-names>S.</given-names></name>
<name><surname>Sheth</surname><given-names>D.</given-names></name>
<name><surname>Boddu</surname><given-names>S.H.S.</given-names></name>
<name><surname>Patel</surname><given-names>C.</given-names></name>
</person-group><article-title>Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials</article-title><source>Rev. Med. Virol.</source><year>2024</year><volume>34</volume><fpage>e2507</fpage><pub-id pub-id-type="doi">10.1002/rmv.2507</pub-id><pub-id pub-id-type="pmid">38282394</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01365"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Griffin</surname><given-names>D.W.J.</given-names></name>
<name><surname>Pai Mangalore</surname><given-names>R.</given-names></name>
<name><surname>Hoy</surname><given-names>J.F.</given-names></name>
<name><surname>McMahon</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV</article-title><source>AIDS.</source><year>2023</year><volume>37</volume><fpage>1345</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003579</pub-id><pub-id pub-id-type="pmid">37070539</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01365"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Negredo</surname><given-names>E.</given-names></name>
<name><surname>Domingo</surname><given-names>P.</given-names></name>
<name><surname>Sambeat</surname><given-names>M.A.</given-names></name>
<name><surname>Rabella</surname><given-names>N.</given-names></name>
<name><surname>V&#x000e1;zquez</surname><given-names>G.</given-names></name>
</person-group><article-title>Effect of pneumococcal vaccine on plasma HIV-1 RNA of stable patients undergoing effective highly active antiretroviral therapy</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2001</year><volume>20</volume><fpage>287</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1007/s100960100470</pub-id><pub-id pub-id-type="pmid">11399023</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01365"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rey</surname><given-names>D.</given-names></name>
<name><surname>Krantz</surname><given-names>V.</given-names></name>
<name><surname>Partisani</surname><given-names>M.</given-names></name>
<name><surname>Schmitt</surname><given-names>M.P.</given-names></name>
<name><surname>Meyer</surname><given-names>P.</given-names></name>
<name><surname>Libbrecht</surname><given-names>E.</given-names></name>
<name><surname>Wendling</surname><given-names>M.J.</given-names></name>
<name><surname>Vetter</surname><given-names>D.</given-names></name>
<name><surname>Nicolle</surname><given-names>M.</given-names></name>
<name><surname>Kempf-Durepaire</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>1161</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00389-8</pub-id><pub-id pub-id-type="pmid">10649616</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01365"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000fc;nthard</surname><given-names>H.F.</given-names></name>
<name><surname>Wong</surname><given-names>J.K.</given-names></name>
<name><surname>Spina</surname><given-names>C.A.</given-names></name>
<name><surname>Ignacio</surname><given-names>C.</given-names></name>
<name><surname>Kwok</surname><given-names>S.</given-names></name>
<name><surname>Christopherson</surname><given-names>C.</given-names></name>
<name><surname>Hwang</surname><given-names>J.</given-names></name>
<name><surname>Haubrich</surname><given-names>R.</given-names></name>
<name><surname>Havlir</surname><given-names>D.</given-names></name>
<name><surname>Richman</surname><given-names>D.D.</given-names></name>
</person-group><article-title>Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy</article-title><source>J. Infect. Dis.</source><year>2000</year><volume>181</volume><fpage>522</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1086/315260</pub-id><pub-id pub-id-type="pmid">10669335</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01365"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>H&#x000f6;ft</surname><given-names>M.A.</given-names></name>
<name><surname>Burgers</surname><given-names>W.A.</given-names></name>
<name><surname>Riou</surname><given-names>C.</given-names></name>
</person-group><article-title>The immune response to SARS-CoV-2 in people with HIV</article-title><source>Cell Mol. Immunol.</source><year>2024</year><volume>21</volume><fpage>184</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01087-w</pub-id><pub-id pub-id-type="pmid">37821620</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01365"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sulaiman</surname><given-names>S.K.</given-names></name>
<name><surname>Musa</surname><given-names>M.S.</given-names></name>
<name><surname>Tsiga-Ahmed</surname><given-names>F.I.</given-names></name>
<name><surname>Sulaiman</surname><given-names>A.K.</given-names></name>
<name><surname>Bako</surname><given-names>A.T.</given-names></name>
</person-group><article-title>A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV</article-title><source>Nat. Hum. Behav.</source><year>2024</year><volume>8</volume><fpage>100</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/s41562-023-01733-3</pub-id><pub-id pub-id-type="pmid">37904021</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01365"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaida</surname><given-names>A.</given-names></name>
<name><surname>Brotto</surname><given-names>L.A.</given-names></name>
<name><surname>Murray</surname><given-names>M.C.M.</given-names></name>
<name><surname>C&#x000f4;t&#x000e9;</surname><given-names>H.C.F.</given-names></name>
<name><surname>Albert</surname><given-names>A.Y.</given-names></name>
<name><surname>Nicholson</surname><given-names>V.</given-names></name>
<name><surname>Gormley</surname><given-names>R.</given-names></name>
<name><surname>Gordon</surname><given-names>S.</given-names></name>
<name><surname>Booth</surname><given-names>A.</given-names></name>
<name><surname>Smithm</surname><given-names>L.W.</given-names></name>
<etal/>
</person-group><article-title>Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada</article-title><source>AIDS Behav.</source><year>2022</year><volume>26</volume><fpage>2242</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1007/s10461-022-03577-w</pub-id><pub-id pub-id-type="pmid">35020094</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01365"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>M.</given-names></name>
<name><surname>Santos Aleluia</surname><given-names>I.R.</given-names></name>
<name><surname>de Castro</surname><given-names>C.T.</given-names></name>
<name><surname>de Almeida Oliveira</surname><given-names>T.</given-names></name>
<name><surname>Cunha</surname><given-names>M.S.</given-names></name>
<name><surname>Magno</surname><given-names>L.</given-names></name>
<name><surname>Dourado</surname><given-names>I.</given-names></name>
<name><surname>Barreto</surname><given-names>F.</given-names></name>
<name><surname>Natividade</surname><given-names>M.</given-names></name>
<name><surname>Appiah</surname><given-names>S.C.Y.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Vaccine Acceptance and Hesitancy among People Living with HIV: Review and Meta-Analysis</article-title><source>AIDS Behav.</source><year>2024</year><volume>28</volume><fpage>2193</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1007/s10461-024-04351-w</pub-id><pub-id pub-id-type="pmid">38713281</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01365"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Cui</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1019</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11061019</pub-id><pub-id pub-id-type="pmid">37376408</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01365"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Datwani</surname><given-names>S.</given-names></name>
<name><surname>Kalikawe</surname><given-names>R.</given-names></name>
<name><surname>Waterworth</surname><given-names>R.</given-names></name>
<name><surname>Mwimanzi</surname><given-names>F.M.</given-names></name>
<name><surname>Liang</surname><given-names>R.</given-names></name>
<name><surname>Sang</surname><given-names>Y.</given-names></name>
<name><surname>Lapointe</surname><given-names>H.R.</given-names></name>
</person-group><article-title>T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>661</elocation-id><pub-id pub-id-type="doi">10.3390/v16050661</pub-id><pub-id pub-id-type="pmid">38793543</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01365"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frater</surname><given-names>J.</given-names></name>
<name><surname>Ewer</surname><given-names>K.J.</given-names></name>
<name><surname>Ogbe</surname><given-names>A.</given-names></name>
<name><surname>Pace</surname><given-names>M.</given-names></name>
<name><surname>Adele</surname><given-names>S.</given-names></name>
<name><surname>Adland</surname><given-names>E.</given-names></name>
<name><surname>Alagaratnam</surname><given-names>J.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Ansari</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: A single-arm substudy of a phase 2/3 clinical trial</article-title><source>Lancet HIV</source><year>2021</year><volume>8</volume><fpage>e474</fpage><lpage>e485</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(21)00103-X</pub-id><pub-id pub-id-type="pmid">34153264</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01365"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antinori</surname><given-names>A.</given-names></name>
<name><surname>Cicalini</surname><given-names>S.</given-names></name>
<name><surname>Meschi</surname><given-names>S.</given-names></name>
<name><surname>Bordoni</surname><given-names>V.</given-names></name>
<name><surname>Lorenzini</surname><given-names>P.</given-names></name>
<name><surname>Vergori</surname><given-names>A.</given-names></name>
<name><surname>Lanini</surname><given-names>S.</given-names></name>
<name><surname>De Pascale</surname><given-names>L.</given-names></name>
<name><surname>Matusali</surname><given-names>G.</given-names></name>
<name><surname>Mariotti</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>75</volume><fpage>e552</fpage><lpage>e563</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac238</pub-id><pub-id pub-id-type="pmid">35366316</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01365"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woldemeskel</surname><given-names>B.A.</given-names></name>
<name><surname>Karaba</surname><given-names>A.H.</given-names></name>
<name><surname>Garliss</surname><given-names>C.C.</given-names></name>
<name><surname>Beck</surname><given-names>E.J.</given-names></name>
<name><surname>Wang</surname><given-names>K.H.</given-names></name>
<name><surname>Laeyendecker</surname><given-names>O.</given-names></name>
<name><surname>Cox</surname><given-names>A.L.</given-names></name>
<name><surname>Blankson</surname><given-names>J.N.</given-names></name>
</person-group><article-title>The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with Human Immunodeficiency Virus (HIV)</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>1268</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab648</pub-id><pub-id pub-id-type="pmid">34293114</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01365"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tuan</surname><given-names>J.J.</given-names></name>
<name><surname>Zapata</surname><given-names>H.</given-names></name>
<name><surname>Critch-Gilfillan</surname><given-names>T.</given-names></name>
<name><surname>Ryall</surname><given-names>L.</given-names></name>
<name><surname>Turcotte</surname><given-names>B.</given-names></name>
<name><surname>Mutic</surname><given-names>S.</given-names></name>
<name><surname>Andrews</surname><given-names>L.</given-names></name>
<name><surname>Roh</surname><given-names>M.E.</given-names></name>
<name><surname>Friedland</surname><given-names>G.</given-names></name>
<name><surname>Barakat</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV</article-title><source>HIV Med.</source><year>2022</year><volume>23</volume><fpage>178</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1111/hiv.13188</pub-id><pub-id pub-id-type="pmid">34632695</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01365"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogbe</surname><given-names>A.</given-names></name>
<name><surname>Pace</surname><given-names>M.</given-names></name>
<name><surname>Bittaye</surname><given-names>M.</given-names></name>
<name><surname>Tipoe</surname><given-names>T.</given-names></name>
<name><surname>Adele</surname><given-names>S.</given-names></name>
<name><surname>Alagaratnam</surname><given-names>J.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Ansari</surname><given-names>M.A.</given-names></name>
<name><surname>Bara</surname><given-names>A.</given-names></name>
<name><surname>Broadhead</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e157031</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.157031</pub-id><pub-id pub-id-type="pmid">35192543</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01365"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goel</surname><given-names>R.R.</given-names></name>
<name><surname>Painter</surname><given-names>M.M.</given-names></name>
<name><surname>Apostolidis</surname><given-names>S.A.</given-names></name>
<name><surname>Mathew</surname><given-names>D.</given-names></name>
<name><surname>Meng</surname><given-names>W.</given-names></name>
<name><surname>Rosenfeld</surname><given-names>A.M.</given-names></name>
<name><surname>Lundgreen</surname><given-names>K.A.</given-names></name>
<name><surname>Reynaldi</surname><given-names>A.</given-names></name>
<name><surname>Khoury</surname><given-names>D.S.</given-names></name>
<name><surname>Pattekar</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>abm0829</fpage><pub-id pub-id-type="doi">10.1126/science.abm0829</pub-id><pub-id pub-id-type="pmid">34648302</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01365"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Au</surname><given-names>W.Y.</given-names></name>
<name><surname>Cheung</surname><given-names>P.P.</given-names></name>
</person-group><article-title>Effectiveness of heterologous and homologous COVID-19 vaccine regimens: Living systematic review with network meta-analysis</article-title><source>BMJ</source><year>2022</year><volume>377</volume><fpage>e069989</fpage><pub-id pub-id-type="doi">10.1136/bmj-2022-069989</pub-id><pub-id pub-id-type="pmid">35640925</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01365"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higdon</surname><given-names>M.M.</given-names></name>
<name><surname>Baidya</surname><given-names>A.</given-names></name>
<name><surname>Walter</surname><given-names>K.K.</given-names></name>
<name><surname>Patel</surname><given-names>M.K.</given-names></name>
<name><surname>Issa</surname><given-names>H.</given-names></name>
<name><surname>Espi&#x000e9;</surname><given-names>E.</given-names></name>
<name><surname>Feikin</surname><given-names>D.R.</given-names></name>
<name><surname>Knoll</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>1114</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00409-1</pub-id><pub-id pub-id-type="pmid">35752196</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01365"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>D.P.C.</given-names></name>
<name><surname>Wong</surname><given-names>N.S.</given-names></name>
<name><surname>Wong</surname><given-names>B.C.K.</given-names></name>
<name><surname>Chan</surname><given-names>J.M.C.</given-names></name>
<name><surname>Lee</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Three-Dose Primary Series of Inactivated COVID-19 Vaccine for Persons Living with HIV, Hong Kong</article-title><source>Emerg. Infect. Dis.</source><year>2022</year><volume>28</volume><fpage>2130</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.3201/eid2810.220691</pub-id><pub-id pub-id-type="pmid">36048772</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01365"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group><article-title>Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: A systematic review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><year>2022</year><volume>124</volume><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2022.10.005</pub-id><pub-id pub-id-type="pmid">36241168</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01365"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lapointe</surname><given-names>H.R.</given-names></name>
<name><surname>Mwimanzi</surname><given-names>F.</given-names></name>
<name><surname>Cheung</surname><given-names>P.K.</given-names></name>
<name><surname>Sang</surname><given-names>Y.</given-names></name>
<name><surname>Yaseen</surname><given-names>F.</given-names></name>
<name><surname>Umviligihozo</surname><given-names>G.</given-names></name>
<name><surname>Kalikawe</surname><given-names>R.</given-names></name>
<name><surname>Speckmaier</surname><given-names>S.</given-names></name>
<name><surname>Moran-Garcia</surname><given-names>N.</given-names></name>
<name><surname>Datwani</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>227</volume><fpage>838</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac229</pub-id><pub-id pub-id-type="pmid">35668700</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01365"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vergori</surname><given-names>A.</given-names></name>
<name><surname>Cozzi Lepri</surname><given-names>A.</given-names></name>
<name><surname>Cicalini</surname><given-names>S.</given-names></name>
<name><surname>Matusali</surname><given-names>G.</given-names></name>
<name><surname>Bordoni</surname><given-names>V.</given-names></name>
<name><surname>Lanini</surname><given-names>S.</given-names></name>
<name><surname>Meschi</surname><given-names>S.</given-names></name>
<name><surname>Iannazzo</surname><given-names>R.</given-names></name>
<name><surname>Mazzotta</surname><given-names>V.</given-names></name>
<name><surname>Colavita</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4922</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32263-7</pub-id><pub-id pub-id-type="pmid">35995780</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01365"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minervina</surname><given-names>A.A.</given-names></name>
<name><surname>Pogorelyy</surname><given-names>M.V.</given-names></name>
<name><surname>Kirk</surname><given-names>A.M.</given-names></name>
<name><surname>Crawford</surname><given-names>J.C.</given-names></name>
<name><surname>Allen</surname><given-names>E.K.</given-names></name>
<name><surname>Chou</surname><given-names>C.H.</given-names></name>
<name><surname>Mettelman</surname><given-names>R.C.</given-names></name>
<name><surname>Allison</surname><given-names>K.J.</given-names></name>
<name><surname>Lin</surname><given-names>C.Y.</given-names></name>
<name><surname>Brice</surname><given-names>D.C.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01184-4</pub-id><pub-id pub-id-type="pmid">35383307</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01365"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coburn</surname><given-names>S.B.</given-names></name>
<name><surname>Humes</surname><given-names>E.</given-names></name>
<name><surname>Lang</surname><given-names>R.</given-names></name>
<name><surname>Stewart</surname><given-names>C.</given-names></name>
<name><surname>Hogan</surname><given-names>B.C.</given-names></name>
<name><surname>Gebo</surname><given-names>K.A.</given-names></name>
<name><surname>Napravnik</surname><given-names>S.</given-names></name>
<name><surname>Edwards</surname><given-names>J.K.</given-names></name>
<name><surname>Browne</surname><given-names>L.E.</given-names></name>
<name><surname>Park</surname><given-names>L.S.</given-names></name>
<etal/>
</person-group><article-title>Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults with HIV in the United States</article-title><source>JAMA Netw. Open</source><year>2022</year><volume>5</volume><fpage>e2215934</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.15934</pub-id><pub-id pub-id-type="pmid">35671054</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01365"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keeton</surname><given-names>R.</given-names></name>
<name><surname>Tincho</surname><given-names>M.B.</given-names></name>
<name><surname>Suzuki</surname><given-names>A.</given-names></name>
<name><surname>Benede</surname><given-names>N.</given-names></name>
<name><surname>Ngomti</surname><given-names>A.</given-names></name>
<name><surname>Baguma</surname><given-names>R.</given-names></name>
<name><surname>Chauke</surname><given-names>M.V.</given-names></name>
<name><surname>Mennen</surname><given-names>M.</given-names></name>
<name><surname>Skelem</surname><given-names>S.</given-names></name>
<name><surname>Adriaanse</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Impact of SARS-CoV-2 exposure history on the T cell and IgG response</article-title><source>Cell Rep. Med.</source><year>2023</year><volume>4</volume><fpage>100898</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100898</pub-id><pub-id pub-id-type="pmid">36584684</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01365"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matveev</surname><given-names>V.A.</given-names></name>
<name><surname>Mihelic</surname><given-names>E.Z.</given-names></name>
<name><surname>Benko</surname><given-names>E.</given-names></name>
<name><surname>Budylowski</surname><given-names>P.</given-names></name>
<name><surname>Grocott</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>T.</given-names></name>
<name><surname>Korosec</surname><given-names>C.S.</given-names></name>
<name><surname>Colwill</surname><given-names>K.</given-names></name>
<name><surname>Stephenson</surname><given-names>H.</given-names></name>
<name><surname>Law</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>107915</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.107915</pub-id><pub-id pub-id-type="pmid">37790281</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01365"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calcinotto</surname><given-names>A.</given-names></name>
<name><surname>Kohli</surname><given-names>J.</given-names></name>
<name><surname>Zagato</surname><given-names>E.</given-names></name>
<name><surname>Pellegrini</surname><given-names>L.</given-names></name>
<name><surname>Demaria</surname><given-names>M.</given-names></name>
<name><surname>Alimonti</surname><given-names>A.</given-names></name>
</person-group><article-title>Cellular Senescence: Aging, Cancer, and Injury</article-title><source>Physiol. Rev.</source><year>2019</year><volume>99</volume><fpage>1047</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1152/physrev.00020.2018</pub-id><pub-id pub-id-type="pmid">30648461</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01365"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brauning</surname><given-names>A.</given-names></name>
<name><surname>Rae</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>G.</given-names></name>
<name><surname>Fulton</surname><given-names>E.</given-names></name>
<name><surname>Admasu</surname><given-names>T.D.</given-names></name>
<name><surname>Stolzing</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
</person-group><article-title>Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>1017</elocation-id><pub-id pub-id-type="doi">10.3390/cells11061017</pub-id><pub-id pub-id-type="pmid">35326467</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01365"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>A.</given-names></name>
<name><surname>Madhavan</surname><given-names>M.V.</given-names></name>
<name><surname>Sehgal</surname><given-names>K.</given-names></name>
<name><surname>Nair</surname><given-names>N.</given-names></name>
<name><surname>Mahajan</surname><given-names>S.</given-names></name>
<name><surname>Sehrawat</surname><given-names>T.S.</given-names></name>
<name><surname>Bikdeli</surname><given-names>B.</given-names></name>
<name><surname>Ahluwalia</surname><given-names>N.</given-names></name>
<name><surname>Ausiello</surname><given-names>J.C.</given-names></name>
<name><surname>Wan</surname><given-names>E.Y.</given-names></name>
<etal/>
</person-group><article-title>Extrapulmonary manifestations of COVID-19</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1017</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id><pub-id pub-id-type="pmid">32651579</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01365"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.J.</given-names></name>
<name><surname>Dong</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>G.H.</given-names></name>
<name><surname>Gao</surname><given-names>Y.D.</given-names></name>
</person-group><article-title>Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2023</year><volume>64</volume><fpage>90</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s12016-022-08921-5</pub-id><pub-id pub-id-type="pmid">35044620</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01365"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>W.S.</given-names></name>
<name><surname>Jiang</surname><given-names>F.Y.</given-names></name>
<name><surname>Shu</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>R.</given-names></name>
<name><surname>Cao</surname><given-names>J.M.</given-names></name>
<name><surname>Wang</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Liver injury in COVID-19: A minireview</article-title><source>World J. Gastroenterol.</source><year>2022</year><volume>28</volume><fpage>6716</fpage><lpage>6731</lpage><pub-id pub-id-type="doi">10.3748/wjg.v28.i47.6716</pub-id><pub-id pub-id-type="pmid">36620342</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01365"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ely</surname><given-names>E.W.</given-names></name>
<name><surname>Brown</surname><given-names>L.M.</given-names></name>
<name><surname>Fineberg</surname><given-names>H.V.</given-names></name>
<collab>National Academies of Sciences, Engineering, and Medicine Committee on Examining the Working Definition for Long Covid</collab>
</person-group><article-title>Long Covid Defined</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>391</volume><fpage>1746</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1056/NEJMsb2408466</pub-id><pub-id pub-id-type="pmid">39083764</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01365"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willyard</surname><given-names>C.</given-names></name>
</person-group><article-title>Are repeat COVID infections dangerous? What the science says</article-title><source>Nature.</source><year>2023</year><volume>616</volume><fpage>650</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1038/d41586-023-01371-9</pub-id><pub-id pub-id-type="pmid">37100944</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01365"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Huo</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Jing</surname><given-names>S.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Si</surname><given-names>M.</given-names></name>
<name><surname>Xin</surname><given-names>Y.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Vaccine Hesitancy Among People Living with HIV: A Systematic Review and Meta-Analysis</article-title><source>AIDS Behav.</source><year>2024</year><volume>28</volume><fpage>2183</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.1007/s10461-024-04344-9</pub-id><pub-id pub-id-type="pmid">38625625</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01365-f001"><label>Figure 1</label><caption><p>Flow chart for this study. PWH, people with HIV; COVID-19, coronavirus disease 2019; ART, antiretroviral therapy.</p></caption><graphic xlink:href="vaccines-12-01365-g001" position="float"/></fig><fig position="float" id="vaccines-12-01365-f002"><label>Figure 2</label><caption><p>Median changes in CD4 count and CD4/CD8 ratio before and after vaccination: (<bold>A</bold>) CD4 count at first dose (n = 48); (<bold>B</bold>) CD4/CD8 ratio at first dose (n = 48); (<bold>C</bold>) CD4 count at second dose (n = 124); (<bold>D</bold>) CD4/CD8 ratio at second dose (n = 124); (<bold>E</bold>) CD4 count at third dose (n = 122); (<bold>F</bold>) CD4/CD8 ratio at third dose (n = 122).</p></caption><graphic xlink:href="vaccines-12-01365-g002" position="float"/></fig><fig position="float" id="vaccines-12-01365-f003"><label>Figure 3</label><caption><p>The levels of CD4 count and CD4/CD8 ratio at pre-COVID-19, post-COVID-19, and recently in PWH receiving vaccination (n = 337): (<bold>A</bold>) CD4 count at different time points; (<bold>B</bold>) CD4/CD8 ratio at different time points. COVID-19, coronavirus disease 2019; PWH, people with HIV.</p></caption><graphic xlink:href="vaccines-12-01365-g003" position="float"/></fig><fig position="float" id="vaccines-12-01365-f004"><label>Figure 4</label><caption><p>CD4 count and CD4/CD8 ratio at different vaccination doses and time points (n = 337): (<bold>A</bold>) pre-COVID-19 CD4 count at different vaccination doses; (<bold>B</bold>) pre-COVID-19 CD4/CD8 ratio at different vaccination doses; (<bold>C</bold>) post-COVID-19 CD4 count at different vaccination doses; (<bold>D</bold>) post-COVID-19 CD4/CD8 ratio at different vaccination doses; (<bold>E</bold>) recent CD4 count at different vaccination doses; (<bold>F</bold>) recent CD4/CD8 ratio at different vaccination doses. COVID-19, coronavirus disease 2019.</p></caption><graphic xlink:href="vaccines-12-01365-g004" position="float"/></fig><table-wrap position="float" id="vaccines-12-01365-t002"><object-id pub-id-type="pii">vaccines-12-01365-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparison of ART regimen and HIV-related markers between the matched groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unvaccinated (n = 34)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated (n = 96)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" rowspan="1">ART, n (%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF/AZT+3TC+EFV/NVP </td><td align="center" valign="middle" rowspan="1" colspan="1">28 (82.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (78.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.601</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF/AZT+3TC+LPV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (11.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.759</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Compound agents (BIC/FTC/TAF)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound agents (DTG/3TC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (2.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (6.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.675</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Frequency of COVID-19 infection, n (%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (20.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (11.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.372</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (73.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">76 (79.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (5.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (9.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">HIV markers</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Two months after first dose </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">500.0 (401.0, 676.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">579.0 (455.5, 709.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.511</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">808.5 (680.0, 958.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">780.0 (579.5, 1002.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.585</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65 (0.57, 0.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80 (0.68, 0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.315</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Two months after third dose </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">540.0 (443.5, 694.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">569,9 (442.0, 749.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.554</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">903.5 (690.0, 1000.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">807.5 (628.0, 981.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.185</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64 (0.49, 0.78)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80 (0.56, 1.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Post-COVID-19</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">613.0 (465.0, 757.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">630.0 (444.0, 811.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.803</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">769.0 (606.0, 1099.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">811.5 (573.0, 1038.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.947</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70 (0.56, 0.92)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75 (0.53, 0.96)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.677</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Recent </td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">589.5 (408.0, 742.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">622.5 (470.5, 808.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.343</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count, cells/uL</td><td align="center" valign="middle" rowspan="1" colspan="1">708.0 (576.0, 957.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">762.0 (575.5, 1021.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.470</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73 (0.63, 0.97)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.61, 1.07)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.843</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Ratio of post-COVID-19 to pre-COVID-19 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Post-CD4/pre-CD4 ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (1.01, 1.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 (1.05, 1.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.651</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Post-CD4/CD8)/(pre-CD4/CD8) ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11 (1.01, 1.42)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.20 (1.03, 1.42)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.573</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">Ratio of recent to pre-COVID-19</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Recent-CD4/pre-CD4 ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 (0.97, 1.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20 (0.98, 1.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.637</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Recent-CD4/CD8)/(pre-CD4/CD8) ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 (1.05, 1.67)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.31 (1.08, 1.55)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.739</td></tr></tbody></table><table-wrap-foot><fn><p>Values are number (percentage) or median (interquartile range). Abbreviations: ART, antiretroviral therapy; COVID-19, coronavirus disease 2019.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01365-t003"><object-id pub-id-type="pii">vaccines-12-01365-t003_Table 3</object-id><label>Table 3</label><caption><p>Changes in HIV markers in subgroups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-COVID-19</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-Vaccination</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" rowspan="1">CD4 count &#x0003e; 500 cells/uL (n = 207) </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count</td><td align="center" valign="middle" rowspan="1" colspan="1">695.0 (598.0, 820.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">803.0 (669.0, 988.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count</td><td align="center" valign="middle" rowspan="1" colspan="1">981.0 (760.0, 1245.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">902.0 (700.0, 1174.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.432</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77 (0.59, 1.01)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89 (0.69, 1.13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">CD4/CD8 ratio &#x0003e; 1 (n = 69) </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count</td><td align="center" valign="middle" rowspan="1" colspan="1">701.0 (561.0, 1044.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">848.0 (670.5, 1124.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count</td><td align="center" valign="middle" rowspan="1" colspan="1">632.0 (443.0, 821.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">658.0 (528.5, 958.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.18 (1.06, 1.29)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 (1.09, 1.52)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">ART initiation &#x0003e; 1 year (n = 263)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count</td><td align="center" valign="middle" rowspan="1" colspan="1">589.0 (422.0, 765.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">690.0 (488.0, 888.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count</td><td align="center" valign="middle" rowspan="1" colspan="1">857.0 (639.0, 1131.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">823.0 (631.0, 1097.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.353</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68 (0.48, 0.98)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.61, 1.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" align="center" valign="middle" rowspan="1">No COVID-19 infection (n = 37)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD4 count</td><td align="center" valign="middle" rowspan="1" colspan="1">600.0 (409.0, 750.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">783.0 (430.5, 878.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CD8 count</td><td align="center" valign="middle" rowspan="1" colspan="1">861.0 (518.0, 1251.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">769.0 (565.5, 1341.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.592</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4/CD8 ratio</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73 (0.53, 1.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84 (0.63, 1.24)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Values are median (interquartile range). Abbreviations: COVID-19, coronavirus disease 2019; ART, antiretroviral therapy.</p></fn></table-wrap-foot></table-wrap></floats-group></article>